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Abstract
The endothelial-specific Angiopoietin-Tie2 ligand-receptor system is an important regulator of endothelial activation.
Binding of angiopoietin-2 (Ang-2) to Tie2 receptor renders the endothelial barrier responsive to pro-inflammatory cytokines.
We previously showed that circulating Ang-2 correlated with disease severity in a small cohort of critically ill patients with
anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. The current study reassessed Ang-2 as a
biomarker of disease activity and relapse in AAV. Circulating Ang-2 was measured in 162 patients with severe AAV (BVAS/
WG$3, with or without glomerulonephritis) in a clinical trial. Ang-2 levels during active AAV were compared to levels in the
same patients during remission (BVAS/WG=0). Levels in clinical subsets of AAV were compared, and association with future
disease course was assessed. Ang-2 levels were elevated in severe disease (median 3.0 ng/ml, interquartile range 1.9–4.4)
compared to healthy controls (1.2, 0.9–1.5). However, they did not reliably decline with successful treatment (median
2.6 ng/ml, interquartile range 1.9–3.8, median change 20.1). Ang-2 correlated weakly with BVAS/WG score (r=0.17),
moderately with markers of systemic inflammation (r=0.25–0.41), and inversely with renal function (r=20.36). Levels were
higher in patients with glomerulonephritis, but levels adjusted for renal dysfunction were no different in patients with or
without glomerulonephritis. Levels were higher in patients with newly diagnosed AAV and lower in patients in whom
treatment had recently been started. Ang-2 levels during active disease did not predict response to treatment, and Ang-2
levels in remission did not predict time to flare. Thus, Ang-2 appears to have limited practical value in AAV as a biomarker of
disease activity at time of measurement or for predicting future activity.
Citation: Monach PA, Ku ¨mpers P, Lukasz A, Tomasson G, Specks U, et al. (2012) Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. PLoS
ONE 7(1): e30197. doi:10.1371/journal.pone.0030197
Editor: George C. Tsokos, Beth Israel Deaconess Medical Center, United States of America
Received September 29, 2011; Accepted December 11, 2011; Published January 18, 2012
Copyright:  2012 Monach et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was sponsored by the Vasculitis Clinical Research Consortium which has received support from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases (U54AR057319, RC1 AR058303, and P60 AR047785), the National Center for Research Resources (U54 RR019497), the National
Institute of Neurological Disorders and Stroke (NS064808), and the Office of Rare Diseases Research. The Rituximab in ANCA-Associated Vasculitis (RAVE) trial was
performed with the support of the Immune Tolerance Network (NIH Contract #N01 AI15416), an international clinical research consortium supported by the
National Institute of Allergy and Infectious Diseases and the Juvenile Diabetes Research Foundation. Genentech and Biogen Idec provided the study medications
and partial funding of the clinical trial. For this ancillary study, Genentech had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript. At the Mayo Clinic and Foundation, the trial was supported by a Clinical and Translational Science Award from the National Center
for Research Resources (NCRR) (RR024150-01); at Johns Hopkins University, by grants from the NCRR (RR025005) and career development awards (K24 AR049185
to Dr. Stone, and K23 AR052820 to Dr. Seo); and at Boston University, by a Clinical and Translational Science Award (RR 025771), grants from the National Institutes
of Health (M01 RR00533) and a career development award (K24 AR02224 to Dr. Merkel). Dr. Monach was also supported by an Arthritis Investigator Award from
the Arthritis Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: Dr Ikle ´ is employed by a commercial company (Rho), which
was contracted to manage the clinical data for the RAVE clinical trial. Although Genentech/Biogen-Idec provided funds for the conduct of the RAVE clinical trial,
neither of these companies nor any other commercial entity provided any support for the ancillary study reported in this manuscript. This does not alter the
authors9 adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: pmonach@bu.edu
¤ Current address: Department of Nephrology, Klinikum Fulda, Fulda, Germany
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30197Introduction
ANCA-associated vasculitis (AAV) encompasses granulomatosis
with polyangiitis (GPA, Wegener’s) and microscopic polyangiitis
(MPA), two diseases that used to have high fatality rates but are
now successfully treated with immune-suppressive drugs. After
induction of remission, disease course is highly variable, and
available biomarkers such as titers of anti-neutrophil cytoplasmic
antibodies (ANCA) and markers of systemic inflammation (ESR,
CRP) do not provide adequate information about whether a
patient is currently in remission or is at risk for relapse [1,2,3,
4,5,6,7,8]. In light of the pathophysiology of AAV, circulating
proteins derived from damaged or activated microvascular
endothelial cells are plausible candidates as biomarkers.
Angiopoietins are angiogenic factors essential for vascular
development, maturation, and inflammation [9,10,11,12]. As
circulating or matrix-bound molecules, angiopoietin-1 (Ang-1)
and angiopoietin-2 (Ang-2) bind to the extracellular domain of the
tyrosine kinase receptor Tie2, predominantly expressed on
endothelial cells [13,14]. Constitutive Ang-1 expression by
vascular mural cells, and low-level Tie2 phosphorylation, probably
represent a non-redundant control pathway that maintains vessel
integrity, prevents endothelial hyperpermeability and inhibits
leukocyte-endothelium interactions [9,15]. Upon a variety of
stimuli, Ang-2 is rapidly released by the activated endothelium
from Weibel-Palade bodies [16], disrupts constitutive Ang-1/Tie2
signalling by preventing Ang-1 from binding to Tie2 [13,16,17],
and thereby promotes vascular permeability and leukocyte
adhesion.
Circulating levels of Ang-2 are elevated in multiple disease states
of endothelial activation and/or damage, such as sepsis [18,19,
20,21], systemic lupus erythematosus [22], and hypertension [23].
Elevated Ang-2 levels are associated with multi-system organ failure
in acute pancreatitis [24] and with mortality in critically ill patients
[19]. However, Ang-2 levels also rise moderately during progression
of chronic kidney disease due to either IgA nephropathy or adult
polycystic kidney disease [25], two diseases in which endothelial
damage does not play a primary role.
In our previous study in AAV, serum levels of Ang-2 were much
higher in 15 patients with untreated, severe AAV with glomer-
ulonephritis (GN; 9 with GPA, 6 with MPA) than in three other
groups: i) 20 patients with a history of AAV and GN but in
remission and on minimal immune-suppressive medication at
times of measurement; ii) 10 patients with active GPA limited to
granulomatous disease of the respiratory tract but no evidence of
systemic necrotizing vasculitis, off immune-suppressive drugs, and
iii) 20 healthy age-matched controls [26]. In the 15 patients with
active GN, Ang-2 levels did not correlate with glomerular filtration
rate (GFR), indicating that kidney dysfunction per se was not the
reason for Ang-2 elevation. Eight of these 15 patients also had
samples available 6 months later, after successful treatment, and
Ang-2 levels had returned to the normal range in 7 of these 8
patients.
Several questions were left unanswered by that pilot study. Are
Ang-2 levels elevated in patients with severe AAV without GN?
With treatment, how reliably do levels fall into the normal range?
Do levels prior to treatment predict response to therapy? Do levels
after achievement of remission predict future relapse? We
addressed these questions using samples obtained from patients
enrolled in the Rituximab in ANCA-Associated Vasculitis (RAVE)
clinical trial [27], at times of severe active disease and remission,
and in the Vasculitis Clinical Research Consortium (VCRC)
Longitudinal Study, at times of mild disease, severe disease, or
remission.
Methods
Study Subjects (RAVE, VCRC, and controls)
Subjects with AAV were enrolled in either the Rituximab in
ANCA-Associated Vasculitis (RAVE) trial or the Vasculitis Clinical
Research Consortium (VCRC) Longitudinal Study. Healthy
control subjects were recruited at Boston University School of
Medicine and at Medical College Hannover. All subjects were
enrolled using protocols and written informed consent documents
approved by local institutional review boards/ethics committees at
all institutions at which participants were recruited and/or human
subjects research was performed: Boston University, Cleveland
Clinic, Duke University, Hannover Medical School, Hospital for
SpecialSurgery,JohnsHopkinsUniversity,MayoClinic,McMaster
University, University Medical Center Groningen, University of
South Florida, and University of Toronto.
RAVE was a randomized, double-blinded, multi-center clinical
trial of 197 patients with severe GPA or MPA that compared oral
cyclophosphamide (CYC) to the B-cell-depleting agent rituximab
(RTX) for induction of remission, each treatment combined with a
standardized regimen of glucocorticoids [27]. All patients in the
trial tested positive for antibodies to either proteinase 3 (PR3) or
myeloperoxidase (MPO) at screening. Subjects randomized to
receive CYC were switched to maintenance therapy with
azathioprine (AZA) if they were clinically in remission between
months 4 and 6. Subjects in the RTX arm were not placed on a
maintenance agent but were considered to still be ‘‘on treatment’’
at month 6, since peripheral B cells were still undetectable in most
patients. Prednisone was completely withdrawn before six months
per study protocol. Investigators had the option to restart
prednisone at no more than 10 mg/day to control recurrent
symptoms of mild disease. Achievement of remission, with or
without low-dose prednisone, was equivalent in the two treatment
arms [27].
The VCRC Longitudinal Study is a multi-center, observational
study of patients with six different forms of vasculitis, including
GPA and MPA. Subjects were seen either quarterly or annually,
and also at the time of flare of vasculitis, if possible. Blood samples
were drawn at each visit and were linked to clinical data recorded
on standardized forms.
Patient Subgroups and Covariates (RAVE only)
The following subgroups were defined at the RAVE screening
visit: i) GPA vs. MPA; ii) PR3-ANCA vs. MPO-ANCA; iii) active
vs. inactive renal disease; and iv) newly diagnosed vs. relapsing
disease. Initiation of treatment with glucocorticoids or other
immune-suppressive drugs for severe AAV was allowed within 14
days preceding the screening visit for RAVE, and the presence or
absence of such treatment was recorded using two dichotomous
variables: any immune-suppressive drug, or specifically glucocor-
ticoids. Covariates included age, sex, a diagnosis of hypertension,
and a diagnosis of coronary artery disease.
Selection of Patients and Processing of Samples (RAVE,
VCRC, and controls)
For the RAVE cohort, each patient who had remained in the
trial more than 4 months and from whom an adequate sample
volume had been obtained at screening was included (n=162).
Among those 162 subjects, an additional sample from the month 6
visit was used only if the subject completed month 6 in the original
treatment arm (n=142). Subjects from the VCRC repository were
chosen on the basis of having at least one visit at a time of active
AAV (n=68); additional samples were chosen from the same
patients at times of either active AAV or remission if available. In
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samples per subject. Eighteen controls were available for assay of
Ang-2 in serum, and 30 for assay of Ang-2 in plasma.
Serum (RAVE) and plasma (VCRC) were initially collected,
processed, and stored at each study site, then shipped to central
repositories, and then shipped to the study laboratory. All samples
from RAVE remained frozen at 280uC until the day the assays
were performed. Samples from the VCRC had been thawed and
re-frozen once previously.
Measurement of Vasculitis Disease Activity (RAVE and
VCRC)
In RAVE, activity of AAV was measured using the Birmingham
Vasculitis Activity Score for Wegener’s Granulomatosis BVAS/
WG [28], which summarizes disease activity in the past 28 days,
and in which each severe disease manifestation is given 3 points
and each non-severe manifestation is given 1 point. Remission was
defined as BVAS/WG=0, and active disease as BVAS/WG.0.
In the VCRC, disease activity was assessed using the BVAS/WG
and also by Physician Global Assessment (PGA) on a 0–10 Likert
scale. In both studies, the presence or absence of items on the
BVAS/WG that clearly indicate necrotizing vasculitis was noted.
Longitudinal Outcome Measures (RAVE only)
Success of initial treatment was assessed by classifying subjects
in three related ways. First, patients who remained in their original
treatment groups, were in remission at month 6, and were off
prednisone were compared to patients who did not meet these
criteria. Second, patients in remission at month 6, including
patients who were taking prednisone #10 mg/day, were com-
pared to subjects who did not meet these criteria. Third, patients
described as having a flare of AAV before month 6 were compared
to those who did not have a flare recorded.
Time to flare after successful treatment (in remission at month 6)
was assessed in two ways: time to severe flare (BVAS/WG$3) and
time to flare of any severity (BVAS/WG.0).
Biomarker Assays and Additional Laboratory Data (RAVE
and VCRC)
Circulating Ang-2 levels were measured by immuno-lumino-
metric assay (ILMA, in RAVE samples) or ELISA (VCRC
samples) using a pair of anti-Ang-2 monoclonal antibodies and
recombinant Ang-2 as a standard (R&D, Oxon, U.K.) as described
previously [26,29]. VCRC samples and healthy control samples
were assayed in duplicate, with the average of the two values used
for analysis. The assays have a detection limit of 0.2 ng/mL. Inter-
assay and intra-assay imprecision are ,6%. Ang-2 is stable in
serum and citrated plasma at room temperature for at least 24 h
and is resistant to at least 4 freeze-thaw cycles. Levels in plasma are
not significantly lower than in serum [29].
Westergren erythrocyte sedimentation rate (ESR), C reactive
protein (CRP), and serum creatinine were assayed at the
participating sites. In RAVE, GFR (in ml/min per 1.73 m
2 body
surface area) was estimated from serum creatinine (Cr, in mg/dL)
using the MDRD formula [30].
Ang-2 levels in all samples from RAVE that were associated
with estimated GFR,60 ml/min per 1.73 m
2 body surface area
were also adjusted for the effect of low GFR based on results of
linear regression (see below).
Statistical Analysis
Distributions of Marker Values, and Adjustment for
Multiple Comparisons. Distributions of Ang-2 values were
evaluated for normality using Shapiro-Wilk and Kolmogorov-
Smirnov tests, as well as visual inspection of histograms. Since
Ang-2 levels were not normally distributed among subjects with
active vasculitis in RAVE, all data are reported as medians and
interquartile ranges and were analyzed using non-parametric
statistics. Findings in all analyses were considered significant at
P,0.05, after adjustment for multiple comparisons [31]. All
analyses were performed using SAS 9.1 (SAS Institute, Cary, NC).
Comparing Active AAV to Remission or to Healthy
Controls (RAVE and VCRC). In RAVE, change in Ang-2
level from screening to month 6 among patients in remission at
month 6 was analyzed by Wilcoxon Signed Rank test. Ang-2 levels
adjusted for the effect of low GFR were also analyzed in this way.
Correlation of (unadjusted) Ang-2 level with BVAS/WG score at
screening was analyzed using Spearman coefficients. Comparisons
of Ang-2 levels between i) patients at screening and healthy
controls, ii) patients in remission at month 6 and healthy controls,
and iii) patients with recurrent or persistently active disease at
month 6 and patients in remission, were analyzed by Wilcoxon
Rank Sum tests.
In the VCRC, Ang-2 levels in samples associated with active
AAV, AAV in remission, and healthy controls were compared by
Wilcoxon Rank Sum tests. Correlation of Ang-2 level with BVAS/
WG score or PGA was measured by Spearman coefficients. Since
patients contributed 1–6 samples and had variable numbers of
visits characterized by active disease or remission, association of
Ang-2 with active AAV was also tested using generalized linear
models (GLM) in which patient identification numbers were
included along with disease activity measures (active disease or
remission, or BVAS/WG score, or PGA) as independent variables
modeling Ang-2 level as the dependent variable.
Clinical Subsets, Covariates, and Laboratory Parameters
(RAVE only). Marker levels at screening in dichotomous
subgroups were compared using Wilcoxon Rank Sum tests
(GPA vs. MPA, PR3-ANCA vs. MPO-ANCA, male vs. female,
new vs. relapsing disease, treated vs. untreated, and presence
vs. absence of active renal disease, alveolar hemorrhage,
hypertension, or coronary artery disease). Ang-2 levels in some
of these subgroups (GPA/MPA, ANCA specificity, new/relapsing,
treated/untreated, active renal disease, or alveolar hemorrhage)
were also analyzed after adjustment for effects of low GFR.
Correlation of Ang-2 levels with continuous variables (ESR,
CRP, age or GFR) was assessed using Spearman coefficients, in all
subjects at screening or in subjects in remission at month 6. Linear
regression was used to estimate the average change in Ang-2
associated with rise in age and/or decline in GFR (age and/or
GFR as independent variable(s), Ang-2 level as dependent
variable). The beta coefficient of the linear regression of Ang-2
vs. GFR among subjects in remission at month 6 in RAVE was
used to adjust Ang-2 levels for GFR,60 ml/min per 1.73 m
2,a s
noted above. Spearman correlation of Ang-2 levels with ESR and
CRP was also measured in the VCRC cohort.
Post-hoc Analysis of Subjects with Untreated, Newly-
Diagnosed AAV with Renal Involvement, and of Subjects
with the Highest Ang-2 Levels (RAVE only). Subjects in
RAVE who most closely resembled the subjects in our previous
study [26] were selected in three ways. First, Ang-2 levels in
subjects with newly-diagnosed AAV who had not yet been treated
were compared to subjects not meeting these criteria, by Wilcoxon
Rank Sum test. Second, Ang-2 levels in subjects with newly-
diagnosed AAV including GN who had not yet been treated were
compared to subjects not meeting these criteria. Third, the clinical
features of the 15 subjects with Ang-2.6 ng/ml at screening were
compared to those of the 147 subjects with lower levels. Age, GFR,
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tests, and the frequencies of GPA (vs. MPA), newly-diagnosed
AAV (vs. relapsing), current treatment (vs. untreated), active GN,
and active alveolar hemorrhage were compared by Fisher Exact
tests.
Prediction of Response to Treatment, or of Future
Relapse (RAVE only). For prediction of response to
treatment, Ang-2 levels at screening were compared, using
Wilcoxon Rank Sum tests, in groups defined by three related
outcomes at month 6, as defined above.
For prediction of future relapse in RAVE, analysis was limited
to subjects in remission, in their original treatment groups, and off
prednisone at month 6 (n=104). Ang-2 level at month 6,
treatment group (CYC/AZA or RTX), ANCA specificity, new
or relapsing disease at screening, age, and sex were used as
independent variables to predict two separate outcomes (time to
severe flare, and time to any flare) as defined above. All variables
associated individually with time to flare at P,0.2 were then
included as covariates alongside Ang-2 in multivariable Cox
proportional hazards models.
Results
Ang-2 in Active AAV and Remission (RAVE and VCRC)
All 162 subjects from RAVE who were included in the current
study had severe disease at screening, with median BVAS/
WG=8, interquartile range 6–10 (Table 1). One hundred thirty-
eight patients had at least one manifestation on the BVAS/WG
that indicated necrotizing vasculitis rather than merely a
combination of granulomatous, musculoskeletal, and constitution-
al features. Serum Ang-2 levels in these 162 patients were higher
than in 18 healthy controls: median 3.0 (interquartile range 1.8–
4.4) vs. 1.2 (0.9–1.5) ng/ml, P,0.0001.
One hundred forty-two of these 162 subjects completed 6
months in their original treatment groups and had samples
available at month 6; of those 142, 120 were in remission and 22
had recurrent or persistent, usually mild disease (median BVAS/
WG=1, interquartile range 1–2). Among the 120 subjects in
remission at month 6, there was no significant difference in serum
Ang-2 between screening and remission. The median decrease was
0.1 ng/ml with a broad range (Table 2 and Figure 1A), and
levels remained higher than among healthy controls (P,0.0001).
Results were similar among the 22 subjects who had recurrent or
persistent disease at month 6 (Table 2 and Figure 1A).
The VCRC cohort included 81 samples from 68 subjects at
times of active disease: median BVAS/WG=2, interquartile
range 1–4, full range 1–7 (Table 1). Among these 81 samples, 26
were associated with necrotizing vasculitis, and the other 55 with
granulomatous, musculoskeletal, and/or constitutional manifesta-
tions. Thus, disease severity was lower than for the patients in
RAVE at screening visits. Fifty-four samples from among the same
68 patients at times of remission were also measured. Plasma Ang-
2 levels were no higher in samples taken at times of active disease
(median 1.2 [interquartile range 0.9–1.9] ng/ml) than in samples
taken during remission (1.1 [0.8–1.7] ng/ml; P=0.33) or from 30
healthy controls (1.1 [0.8–1.4] ng/ml; P=0.08). However, Ang-2
levels were somewhat higher in the 26 samples associated with
necrotizing vasculitis (1.6 [1.1;2.6] ng/ml) than in the 55 samples
representing only non-vasculitic manifestations (1.1 [0.8;1.9] ng/
ml; P=0.03) or in the 54 samples reflecting remission (1.1 [0.9;1.4]
ng/ml; P=0.004).
Among the 162 patients at screening in RAVE, there was a
statistically significant but weak association between serum Ang-2
and BVAS/WG: r=0.17, P=0.03 (Figure 1B). Because the
BVAS/WG reflects disease activity in the past 28 days, and some
patients in RAVE had begun treatment within the past 14 days, a
separate analysis was performed limited to untreated patients, in
whom the BVAS/WG score clearly indicates disease activity at the
time of sample collection. The association of Ang-2 with BVAS/
WG in these 73 patients was unchanged: r=0.18. In the VCRC,
there was no significant correlation between plasma Ang-2 and
either BVAS/WG score (r=0.11, P=0.20) or PGA (r=0.13,
P=0.15; see Figure 1C). Restricting the correlation analysis to
subjects with active disease (BVAS/WG.0 and PGA.0) did not
change the results, nor did accounting for the presence of variable
numbers of active and remission visits from different subjects (data
not shown, see Methods).
Table 1. Demographic and disease-related features of the
patients in this study.
RAVE (n=162) VCRC (n=68)
Age* 52 (44;66) 52 (36;60)
Sex (female) 83 (51%) 40 (59%)
AAV subtype (GPA) 126 (78%) 65 (96%)
Active disease samples 162{ 81
Active treatment 89 (55%) 69 (85%)
Glucocorticoid treatment 78 (48%) 64 (79%)
BVAS/WG* 8 (6;10) 2 (1;4)
Necrotizing vasculitis 138 (85%) 26 (32%)
Remission samples 120 54
Active treatment 120 (100%) 44 (81%)
Glucocorticoid treatment 15 (13%) 38 (70%)
GPA=granulomatosis with polyangiitis.
*Median (interquartile range).
{Data shown regarding active disease are limited to samples at screening.
Twenty-two of these patients also had active disease of lower severity at
month 6: median BVAS/WG=1 (interquartile range 1–2).
doi:10.1371/journal.pone.0030197.t001
Table 2. Ang-2 levels in patients with severe active ANCA-associated vasculitis and in the same patients after treatment in the
RAVE trial.
Clinical Status at Month 6 Screening Month 6 Difference, Screening minus Month 6 P*
Remission (n=120) 3.0 (1.9;4.4) 2.6 (1.9;3.8) 0.1 (20.7;1.3) 0.099
Active (n=22) 2.7 (1.8;4.5) 2.9 (1.9;4.3) 0.05 (20.8;0.7) 0.99
All values indicate serum Ang-2 in ng/ml; medians and interquartile ranges are shown.
*Comparing the difference (screening minus month 6) to the null distribution (Wilcoxon Signed Rank test); P=0.57 comparing the differences seen in Month 6
Remission and Month 6 Active, P=0.6 comparing Remission with Active at month 6 (Wilcoxon Rank Sum test).
doi:10.1371/journal.pone.0030197.t002
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30197Figure 1. Angiopoietin-2 (Ang-2) levels at different levels of disease activity in ANCA-associated vasculitis. A. Serum levels in
individual patients in the RAVE trial before (Screening) and after (Month 6) treatment, stratified by whether patients were in remission (left panel)o r
had recurrent disease (right panel) at month 6. B. Plot of serum Ang-2 versus BVAS/WG score in individual subjects in RAVE at screening. Each patient
had severe disease and therefore a BVAS/WG score of at least 3. C. Plot of plasma Ang-2 versus two measures of disease activity in the VCRC
longitudinal study: Physician Global Assessment (PGA, left panel) and BVAS/WG score (right panel). Note that patients in remission (PGA=0 and
BVAS/WG=0) are included, and that Ang-2 levels are lower in plasma than in serum.
doi:10.1371/journal.pone.0030197.g001
Figure 2. Plots of angiopoietin-2 (Ang-2) levels versus markers of systemic inflammation. A. Serum Ang-2 versus ESR (left panel) and CRP
(right panel) in the RAVE trial. Values at screening, when each patient had severe disease (BVAS/WG$3), are shown. B. Plasma Ang-2 versus ESR (left
panel) and CRP (right panel) in the VCRC longitudinal study. Note that patients in remission (BVAS/WG=0) are included, and that Ang-2 levels are
lower in plasma than in serum.
doi:10.1371/journal.pone.0030197.g002
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VCRC)
As shown in Figure 2A, among the 162 subjects with active
AAV at screening in RAVE, serum Ang-2 correlated moderately
well with ESR (r=0.38, P,0.0001) and CRP (r=0.35,
P,0.0001). In the VCRC, correlation of plasma Ang-2 with
ESR and CRP were of similar magnitude (Figure 2B), regardless
of whether analysis was restricted to the 81 samples associated with
active disease (r=0.41 and 0.33, P=0.0005 and P=0.008,
respectively) or included the 54 remission samples (r=0.35 and
0.25, P,0.0001 and P=0.008, respectively).
Ang-2 in Subsets of AAV (RAVE only)
The 162 subjects in RAVE at screening were classified
according to AAV subtype (GPA or MPA), ANCA specificity,
presence or absence of renal disease or alveolar hemorrhage, and
newly diagnosed or established AAV. Ang-2 levels were higher in
patients with active renal disease or with a new diagnosis of AAV,
although differences were modest (Table 3).
In order to address the possibility that impaired renal function
had a direct effect on Ang-2 levels, association of Ang-2 with
GFR was measured not only among subjects at screening (median
60 ml/min/1.73 m
2, interquartile range 36–79), but more
importantly among subjects in remission at month 6 (median
61, interquartile range 41–74), so as to avoid active GN as a
confounder. A significant negative association was found
particularly among subjects in remission (r=20.23, P=0.005
at screening; r=20.36, P,0.0001 at month 6; Figure 3),
corresponding to an average increase in serum Ang-2 of 0.18 ng/
ml (6 SE 0.05) per 10 ml/min/1.73 m
2 reduction in GFR using
the data at month 6. Re-analysis of changes in Ang-2 levels after
treatment and of Ang-2 levels in clinical subgroups at screening
using Ang-2 levels adjusted for the effect of low GFR changed
only one of the conclusions to be drawn from Tables 1, 2, and 3:
subjects with active GN no longer had higher values than subjects
with active AAV without GN (median 2.8 vs. 2.5 ng/ml,
P=0.33).
Effects of Treatment, GFR, and Other Covariates (RAVE
only)
Subjects who were already being treated with glucocorticoids
and/or other immune-suppressive drugs at the time of screening in
RAVE had lower levels of Ang-2 than did patients who had not
yet been treated (Table 4). Doses of glucocorticoids were not
available but were presumed to be at or near 1 mg/kg since these
patients were being treated for severe flares, and duration of such
treatment was no more than 2 weeks per study protocol. Among
patients in remission at month 6, levels did not differ between
patients treated with CYC/AZA versus those treated with RTX,
Table 3. Ang-2 levels in clinical subgroups of active ANCA-
associated vasculitis in the RAVE trial.
Subgroups* N
{ Yes
{ No
{ P
GPA (vs. MPA) 126,36 2.9 (1.8;4.2) 3.1 (2.15;5.4) 0.20
PR3 ANCA (vs. MPO) 112,50 2.95 (1.8;4.2) 3.0 (2.1;4.6) 0.56
Renal Disease 79,83 3.1 (2.2;4.4) 2.5 (1.7;4.5) 0.042
Alveolar Hemorrhage 42,120 2.7 (1.9;3.5) 3.05 (1.8;4.5) 0.25
New Diagnosis 77,85 3.5 (2.4;5.3) 2.4 (1.7;3.4) 0.0001
*All data (clinical subgroups and Ang-2 levels) were obtained at screening.
GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis;
PR3=proteinase 3; MPO=myeloperoxidase.
{Numbers of subjects fulfilling and not fulfilling the subgroup designation.
{Serum Ang-2 (ng/ml) in subjects fulfilling (Yes) and not fulfilling (No) the
subgroup designation; medians and interquartile ranges are shown.
doi:10.1371/journal.pone.0030197.t003
Figure 3. Plots of serum angiopoietin-2 (Ang-2) levels versus GFR (top panels) or age (bottom panels). Samples from subjects in RAVE
were assayed at times of active AAV (screening, left panels) and remission 6 months after starting treatment (right panels).
doi:10.1371/journal.pone.0030197.g003
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glucocorticoids had been restarted (Table 4).
Other covariates were assessed among subjects in remission at
month 6 so as to eliminate active AAV as a contributor to Ang-2
levels. Levels did not differ between subjects with or without
diagnoses of coronary artery disease or hypertension, nor between
men and women (Table 4). Ang-2 levels increased significantly
with age (r=0.23, P=0.003 at screening; r=0.34, P=0.0002 at
month 6; Figure 3), corresponding to an average increase of
0.29 ng/ml per 10 years of age using the data at month 6. Because
ageandGFRwerenegativelycorrelatedwitheachother(r=20.39,
P,0.0001 at screening; r=20.42, P,0.0001 at month 6), multiple
linear regression was performed, which suggestedthat age and GFR
provided some independent information but were predominantly
measuringthesamepredictive factor: P=0.04 for each variable and
R
2=0.11 in the combined model, compared to P=0.002 and
R
2=0.08 for either variable individually.
Post-hoc Analysis of Subsets Resembling the Previously-
Studied Cohort (RAVE only)
Because these results differed from those in our previous study
[26], an additional analysis of RAVE patients at screening was
limited to those who more closely resembled those in the earlier
report: patients with newly-diagnosed AAV and not yet treated.
The 57 subjects who met these criteria had median Ang-2 of
3.2 ng/ml (interquartile range 2.4–5.5), compared to 2.8 (1.8–3.7)
ng/ml for the 105 subjects not meeting these criteria, P=0.002.
Further restricting the subset to newly-diagnosed, untreated
patients with active GN had little if any effect: the 33 subjects
who met these criteria had median Ang-2 of 3.7 (2.2–4.7) ng/ml,
compared to 2.9 (1.8–4.1) ng/ml for the 129 subjects not meeting
these criteria, P=0.07.
The subset of 15 patients with Ang-2.6 ng/ml at screening was
also compared to the 147 patients with lower levels. This subset
had higher BVAS/WG scores and was more likely to have newly-
diagnosed and untreated disease, but was not significantly more
likely to have GN (Table S1).
Ang-2 and Prediction of Response to Treatment or
Duration of Remission (RAVE only)
Serum Ang-2 levels at screening in RAVE were no different in
patients who i) did or did not achieve remission off prednisone at
month 6, ii) did or did not achieve remission by month 6 on no
more than 10 mg/day prednisone, or iii) did or did not have a
flare of AAV before month 6 (Table 5).
Although Ang-2 levels among patients in remission were higher
than in healthy controls (see above), these levels were not
predictive of time to severe flare (BVAS/WG$3) or time to flare
of any severity, either as the only predictive variable or in
combination with other clinical variables associated with risk of
relapse (Table 6). Results were similar regardless of whether Ang-
2 level was treated as an untransformed or log-transformed
variable (data not shown).
Discussion
This large study of patients with AAV, followed longitudinally
so that samples were obtained during both active disease and
remission, confirmed that circulating Ang-2 levels are elevated
during severe active AAV but not mild AAV, but failed to confirm
that levels decline after 6 months of successful treatment [26].
Furthermore, levels during active disease were not predictive of
success or failure of treatment, and levels during remission were
not predictive of time to flare.
Sub-group analyses help to reconcile the current results with the
more striking findings of our previous report, in which all patients
had active GN, half were newly diagnosed and not yet treated, and
the half who were having relapses were either untreated or only on
low dose glucocorticoids [26]. Similarly, in the current study,
subjects with GN had higher Ang-2 levels than those without GN;
subjects with newly-diagnosed AAV had higher levels than subjects
with relapsing AAV; subjects who were untreated had higher levels
than subjects already on an immune-suppressive drug at the time of
screening; and untreated subjects with newly-diagnosed AAV had
higher levels than subjects not meeting these criteria. In addition,
the extent of renal impairment among patients with GN was
somewhat lower in the currentstudy than in the previous one: mean
GFR 62636 ml/min compared to 43628 ml/min in the previous
study (using the Cockcroft-Gault formula to allow comparison).
Indeed, analyses of Ang-2 and GFR in patients clinically in
remission suggested that low GFR had an effect on Ang-2 levels, as
Table 4. Effects of treatment or covariates on Ang-2 levels in
the RAVE trial.
Treatment at
Screening* N
1 Yes
" No
" P
On Treatment 89,73 2.7 (1.8;3.7) 3.1 (2.3;5.0) 0.011
On Glucocorticoids 78,84 2.8 (1.7;3.7) 3.1 (2.2;4.7) 0.033
Treatment at month 6
{ N
1 Yes
" No
" P
RTX (vs. CYC/AZA) 65,50 2.5 (1.8;3.7) 2.8 (2.1;3.9) 0.28
On Prednisone 15,105 1.9 (1.4;2.5) 2.7 (2.0;3.9) 0.007
Covariate
{ N
1 Yes
" No
" P
Hypertension 41,79 3.0 (1.9;4.4) 2.6 (1.9;3.5) 0.22
Coronary Artery Disease 7,113 2.6 (1.8;3.9) 2.6 (1.9;3.8) 0.93
Male (vs. Female) 58,62 2.6 (1.9;3.9) 2.6 (1.9;3.8) 0.96
*Values at screening. ‘‘On Treatment’’=glucocorticoids or any other immune-
suppressive drug.
{Values at month 6 restricted to subjects in remission. RTX=rituximab. CYC/
AZA=cyclophosphamide followed by azathioprine. Only subjects who were
still in their original treatment groups were included in the RTX vs. CYC/AZA
analysis.
{Values at month 6 restricted to subjects in remission.
1Numbers fulfilling and not fulfilling the criteria in column one.
"Serum Ang-2 (ng/ml) in subjects fulfilling (Yes) and not fulfilling (No) the
criteria in column one; medians and interquartile ranges are shown.
doi:10.1371/journal.pone.0030197.t004
Table 5. Lack of association of Ang-2 levels during active AAV
with response to treatment in the RAVE trial.
Outcome* N
{ Yes
{ No
{ P
Primary Endpoint 98,59 3.0 (1.9;4.4) 2.9 (1.8;4.4) 0.63
Remission 122,35 3.0 (1.9;4.4) 2.6 (1.8;3.8) 0.44
Flare 33,124 2.9 (1.8;4.5) 2.9 (1.9;4.2) 0.85
*Primary Endpoint=completed month 6 per study protocol, in remission and
not on prednisone. Remission=in remission at month 6 regardless of whether
primary endpoint was met. Flare=worsening disease, or active disease
following a period of remission, during the first six months of treatment.
{Numbers fulfilling and not fulfilling the criteria in column one.
{Serum Ang-2 (ng/ml) in subjects fulfilling (Yes) and not fulfilling (No) the
criteria in column one; medians and interquartile ranges are shown.
doi:10.1371/journal.pone.0030197.t005
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due to IgA nephropathy or polycystic kidney disease [25]. We have
previously discussed why this association is more likely to be related
to endothelial dysfunction rather than reduced clearance of Ang-2
[25]. Reduced GFR probably contributes to elevation of Ang-2 in
active AAV and may be the only reason that patients with GN have
higher levels than patients without GN. However, GFR is not the
driving force for elevation of Ang-2 in severe AAV overall based on
the data shown in Figure 3 and our previous finding that Ang-2 did
not correlate with GFR in severe AAV with GN [26]. Similarly, the
persistent elevation of Ang-2 in many patients clinically in remission
cannot be explained by chronic kidney disease with reduced GFR,
since adjustment of Ang-2 levels for low GFR did not change the
median value (2.6 ng/ml) in such patients.
Other markers of endothelial activation or damage have been
reported to be elevated in patients with active AAV, including
endothelial microparticles [32], intercellular adhesion molecule-
1 (ICAM-1) [33,34,35,36,37], thrombomodulin [38,39], vascular
cell adhesion molecule-1 (VCAM-1) [33,34,36,37,40], and von
Willebrand factor [38]. These studies have also reported either
decline in marker level after treatment, and/or significantly
lower levels among different patients with AAV in remission,
and/or correlation with indices of disease activity, as we also
reported in our pilot study of Ang-2 [26]. However, in several
studies, the ranges of values among patients in remission
appeared to be broader than the ranges in healthy controls
[32,35,36,39], as we have found for Ang-2 in the previous [26]
and current studies and also for thrombomodulin [41] and
ICAM-1 (Monach et al, unpublished data) using data after 6
months of treatment in the RAVE trial. It remains unclear
whether persistent elevation of such markers has any implica-
tions regarding risk of relapse or progression of vascular disease
by other mechanisms.
This study suggests that treatment with immune-suppressive
drugs may lead directly and rapidly to reduction in Ang-2 levels,
based on comparison of treated and untreated subjects at
screening in RAVE and on comparison of patients in remission
at month 6 who were or were not taking prednisone. One
limitation of this study is that this suggestion cannot be directly
tested due to the absence of short-term longitudinal data on
previously untreated patients. Conversely, the strengths of this
study include the use of two relatively large, prospective cohorts
with well-defined and diverse manifestations of AAV, and the use
of a treatment protocol in the larger of those cohorts.
Our data indicate that circulating Ang-2 levels have little promise
as a clinically useful biomarker in AAV. Although Ang-2 is elevated
in other vasculopathic conditions [19,22,23,29], Ang-2 levels have
not been shown to differentiate among vascular diseases. The
current study also suggests that Ang-2 levels are not useful in AAV
to gauge prognosis or assess efficacy of intervention. Finally,
although Ang-2 levels in AAV probably reflect to some extent the
burden of disease (i.e., in a broad range along the continuum of
values reported in hypertension, systemic lupus erythematosus, and
sepsis, and as reflected in correlation with ESR, CRP, and BVAS/
WG values), this effect is not sufficiently strong to distinguish
between severe AAV and remission. The possibility that persistent
elevation of Ang-2 after induction of remission reflects vascular
damage that could predispose to progression of renal insufficiency
or atherosclerosis remains a viable and testable hypothesis.
Supporting Information
Table S1 * Medians and interquartile ranges, or pro-
portions of subjects fulfilling the subgroup designation.
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{Severe flare=BVAS/WG$3.
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